Xilio Therapeutics
33 hedge funds and large institutions have $9.03M invested in Xilio Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
13% more capital inflows, than outflows
Capital inflows: $2.85M | Capital outflows: $2.52M
10% more funds holding
Funds holding: 30 → 33 (+3)
2.06% more ownership
Funds ownership: 57.59% → 59.65% (+2.1%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$267K |
| 2 |
Morgan Stanley
New York
|
+$143K |
| 3 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$118K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$72.6K |
| 5 |
Bridgeway Capital Management
Houston,
Texas
|
+$63.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harvard Management Company
Boston,
Massachusetts
|
-$878K |
| 2 |
Octagon Capital Advisors
New York
|
-$754K |
| 3 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$479K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$320K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$55.8K |
XLO Hedge Fund Activity: Q4 2023 in Review
33 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2023, worth a combined $9.03M — down 73% from $33.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XLO positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $267K. The largest seller was Harvard Management Company, exiting entirely with an estimated $878K sold.
- 33 institutional investors held Xilio Therapeutics (XLO) as of Q4 2023, up from 30 in Q3 2023.
- Funds reported $9.03M of Xilio Therapeutics stock for Q4 2023, down 73% quarter-over-quarter.
- 6 funds opened new Xilio Therapeutics positions in Q4 2023 and 3 closed out, a net change of +3 holders.
- The largest Xilio Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $267K added.
- The largest Xilio Therapeutics seller in Q4 2023 was Harvard Management Company, an estimated $878K sold.
Based on aggregated 13F filings for Q4 2023.